Solventum (NYSE:SOLV) Posts Better

Solventum (NYSE:SOLV) reported Q2 CY2026 results with revenue up 2.2% year on year to $2.21 billion, beating market expectations. Non-GAAP EPS was $2.55, 33.8% above analysts’ consensus. The article also cites trailing 12-month sales of $8.31 billion, flat over two years, and Q2 free cash flow of $144 million. Shares rose 3.7% to $90.75.

Original reporting
Published Aug 5, 2026, 10:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Solventum (NYSE:SOLV) Posts Better — source image
Decision brief

The 30-second read

$SOLVBullishMed
01

Why it matters

Q2 beat likely drives near-term sentiment, but the forward view of flat revenue and longer-term margin pressure suggest traders should watch for evidence that transformation lifts organic growth and cash generation.

02

Market read

A company-specific earnings beat with modest growth and a flat forward revenue outlook creates a mixed setup: supportive for the stock immediately, but potentially range-bound without stronger guidance or organic acceleration.

03

What to watch

Free cash flow margin fell over five years and Q2 margin was only 6.5%, so investors may scrutinize whether transformation increases cash intensity rather than improving it.

Relevance 8/10Novelty 7/10Timing: post-results, immediately after-hours/next-session reaction

Background

The piece frames Solventum’s Q2 CY2026 results versus revenue and EPS consensus, then discusses longer-term revenue and free cash flow trends.

Company-level read

Ticker impact

$SOLVBullishMedium confidence
Context

Solventum reported Q2 CY2026 revenue of $2.21B (+2.2% YoY) and non-GAAP EPS $2.55, beating consensus estimates.

Expected impact

Likely supports a short-term bid, with follow-through dependent on whether management’s transformation improves organic growth and free cash flow margins.

Evidence & confidence

The article provides concrete Q2 results versus consensus and notes analysts expect flat revenue over the next 12 months, which can cap multiple expansion despite the beat.

Market effects

Healthcare services and solutions names may see mild sentiment spillover if investors interpret the transformation as improving earnings quality.

No specific regional catalyst beyond US healthcare earnings sentiment.

Limited, as the disclosed items are company-specific financial results.

Counterpoint

Despite the beat, the article flags flat two-year revenue and expects flat revenue over the next 12 months, implying the outperformance may not translate into sustained growth.

Key entities

  • Solventum

    Healthcare solutions provider reporting Q2 CY2026 results and discussing transformation, organic revenue, and free cash flow.

  • Bryan Hanson

    Solventum CEO quoted on execution and transformation progress.

Related articles

$SOLVMedAI 8/10

Solventum to hive off healthcare software business, raises profit forecast

Solventum said it will separate its health information systems software business, leaving MedSurg and Dental Solutions, as part of its turnaround. The unit accounted for 16.3% of 2025 sales. Solventum raised 2026 organic sales growth to 2.5% to 3% and adjusted profit per share to $7.10 to $7.20. Q2 adjusted EPS was $2.55 on revenue of $2.21B, beating LSEG estimates.

$SOLVHighAI 9/10

Solventum Reports Second Quarter 2026 Financial Results

Solventum (NYSE: SOLV) reported Q2 2026 sales of $2.2 billion, up 2.2% reported and 9.5% organic. GAAP diluted EPS was $0.53, adjusted $2.55. Operating cash flow was $227 million and free cash flow $144 million. The company said it intends to separate its Health Information Systems segment and raised full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow.

$SOLVHigh

Solventum Corp (SOLV): Results of Operations and Financial Condition

Solventum Corp (SOLV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026-8kerexx991.htm EX-99.1 Document Exhibit 99.1 Solventum Reports Second Quarter 2026 Financial Results • R eported sales increased 2.2%; organic sales increased 9.5% • Announces intent to separate its Health Information Systems business segment • Increases full-yea

$SOLVMedAI 8/10

Weekly Research Analysts’ Ratings Changes for Solventum (SOLV)

Solventum (NYSE: SOLV) saw multiple analyst rating and target changes. Wedbush initiated coverage with an “outperform” rating and $94 target (5/15/26). UBS downgraded to “neutral” with $50 target (5/14/26) and previously cut its target to $78 (5/6/26). Other firms adjusted targets and ratings on 5/6/26, including Stifel ($90, buy), KeyCorp ($93, overweight), Wells Fargo ($70, equal weight), and BTIG ($89, buy). Director Amy Mcbride Wendell bought 1,475 shares at $68.03 (3/10/26).

$DTMedAI 8/10

Dynatrace Springs on Q1 Figures

Dynatrace (NYSE: DT) reported Q1 FY2027 results for the quarter ended June 30, 2026. Total ARR was $2,136 million, up 17%. Total revenue rose to $555 million, up 16%. Subscription revenue was $530 million. GAAP operating income was $71 million and non-GAAP $162 million. CEO Rick McConnell cited 41% organic net new ARR growth and accelerating TTM growth.

$DBXMed

Dropbox Shares Decline Despite Earnings Beat as Revenue Growth Disappoints

Dropbox (DBX) shares fell about 5% premarket to around $32.80 after Q2 2026 results. The company reported adjusted EPS of $0.75 vs $0.74 expected and revenue of $631.5M vs about $627M, but revenue rose only 0.9% year over year. Non-GAAP operating margin improved to 39.7%. Paying users reached 18.19M. William Blair upgraded to Market Perform, while consensus remains Sell.